Novo's Wegovy pill to test demand from consumers with cash

Core Insights - Novo Nordisk's newly approved weight-loss pill, a version of Wegovy, is set to enter the U.S. self-pay market in early January, marking a significant development in the cash-paying consumer market for weight-loss treatments [1] Group 1 - The new oral treatment is expected to be highly effective, positioning it as a test case for the rapidly growing consumer market [1]